



Vaccines Main Areas of interest for Investigator Sponsored Studies

Sanofi is committed to building a strong evidence base in the field of vaccines and vaccination. As such, we are interested in receiving proposals of scientific medical research aligned with our existing and pipeline portfolio. Our priority topics are:

- **Vaccination or Immunization coverage especially for influenza, pertussis, meningococcal and pneumococcal diseases, RSV or COVID-19**, including understanding the predictors of vaccine coverage rates in different populations (e.g. by age group, among health care professionals, in populations with specific health conditions, in pregnancy or other categories such as religious pilgrims, travelers, etc.) as well as studies of interventions to increase vaccine coverage. Novel approaches to data collection and analysis are of specific interest.
- **Studies of safety, immunogenicity, or effectiveness of Sanofi vaccines in sub-populations** within the labeled indication (e.g. high-risk populations including preterm infants) or outside the indication (e.g. age, co administration, regimen, etc.)
- **Benefits of vaccination/immunization and assessment of associated vaccination outcomes beyond the direct infection prevented** (e.g. reduction of cardiovascular outcomes following influenza vaccination).
- **Long term persistence of vaccine-mediated protection** (e.g. pertussis, meningococcal, etc.).
- **Role of cell mediated response in long term immunity**, e.g. yellow fever vaccines, pertussis, etc.
- **Epidemiology or surveillance programs of infectious diseases** for our licensed products (e.g., pertussis and/or pertussis outbreaks polio, meningococcal disease, RSV, Yellow Fever, etc.) and long-term clinical sequelae in specific populations (countries, high-risk patients, etc.).
- **Epidemiology of pneumococcal disease in pediatric and adults**, invasive or not, including otitis; epidemiology of pneumococcal colonization
- **Epidemiology or surveillance programs for acne and Chlamydia Trachomatis**
- **Impact of evolving Bordetella pertussis strains on clinical outcomes and disease control including vaccine effectiveness**
- **Impact of vaccination in pregnancy** in long-term effectiveness and immune response according to primary vaccine series type (acellular pertussis versus whole-cell pertussis)
- **Impact, barriers and facilitators to Pharmacy-Based Immunization** (where possible) in increasing vaccination coverage rates in eligible populations

Sanofi will review each research proposal and provide a written response via our web portal regarding the possibility of financial support, clinical immunology support, and/or vaccine supply.